Background {#Sec1}
==========

Lung cancer is one of the most common cancers diagnosed in adults in Singapore, accounting for approximately 11% of all cancers and 22% of cancer-related deaths from 2011 to 2015 \[[@CR1]\]. Approximately 85% of all lung cancers are classified as non-small-cell tumours and the majority of patients have advanced or metastatic disease (stage IIIB/IV) at diagnosis \[[@CR2]\].

Owing to genetic advancement, mutations in the epidermal growth factor receptor (EGFR), which play a role in tumour development and progression, have been found in a subset of lung adenocarcinomas and have led to a paradigm shift in therapy. The incidence of EGFR mutation is 10--20% in Caucasian populations \[[@CR3]\] but as high as 50% in Asian patients \[[@CR4]\]. Tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib and afatinib have been developed to selectively inhibit EGFR tyrosine kinase activity, and in turn, prevent tumour growth and increase tumour cell apoptosis \[[@CR5], [@CR6]\]. The European Society for Medical Oncology (ESMO) and the Singapore Cancer Network (SCAN) recommend EGFR mutation testing for all patients with advanced NSCLC of non-squamous subtype \[[@CR3], [@CR7]\]. Both guidelines also recommend TKIs for the first-line treatment of advanced NSCLC harbouring an EGFR mutation \[[@CR3], [@CR7]\]. Local clinical experts confirm that the recommendations in these guidelines constitute routine clinical practice in Singapore for patients with NSCLC.

To date, none of the TKIs have been shown to significantly improve overall survival (OS) when compared with standard chemotherapy. Randomised controlled trials however have shown TKIs significantly improved progression-free survival (PFS) over standard chemotherapy in treatment-naïve patients with advanced EGFR mutation positive NSCLC \[[@CR5], [@CR8]--[@CR10]\]. Patients treated with afatinib have also been reported to have better progression-free survival (PFS) compared to patients treated with gefitinib, but the absolute difference was small \[[@CR11]\].

In local clinical practice, pemetrexed-platinum chemotherapy is the preferred platinum doublet used as an alternative to TKIs in view of its better clinical outcomes compared with other chemotherapy regimens \[[@CR7]\]. There is currently only one published randomised trial (LUX-Lung 3) that compares a TKI (afatinib) with pemetrexed-based chemotherapy for the first-line treatment of advanced EGFR mutation positive NSCLC \[[@CR6]\].

For decision-makers, the choice between TKIs or chemotherapy is largely influenced by comparative effectiveness and costs. Therefore, the objective of this study was to evaluate the cost-effectiveness of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive NSCLC to inform local drug subsidy decisions in Singapore.

Methods {#Sec2}
=======

LUX-lung 3 trial {#Sec3}
----------------

LUX-Lung 3 was a global, randomised, open-label phase III trial comparing first-line afatinib (*n* = 229; 40 mg once daily) with pemetrexed plus cisplatin (*n* = 111; PemCis) chemotherapy (500 mg/m^2^ pemetrexed and 75 mg/m^2^ cisplatin once every 21 days for a maximum of 6 cycles) in patients with advanced lung adenocarcinoma with proven EGFR mutations. Treatment arms were balanced in terms of patient demographics and clinical characteristics. Approximately 65% of patients were women, 68% were never-smokers and 72% were East Asian ethnicity. The efficacy endpoints included progression-free survival (PFS) (defined as time from random assignment to disease progression or death), objective response rate (ORR) and overall survival (OS).

Median PFS (investigator-reviewed) for afatinib was 11.1 months compared with 6.7 months for PemCis (hazard ratio \[HR\] 0.49; 95% confidence interval \[CI\]: 0.37 to 0.65; *p* = 0.001) \[[@CR6]\]. OS did not differ between afatinib and PemCis in the overall study population after median follow-up of 41 months (HR 0.88; 95% CI: 0.66 to 1.17; *p* = 0.39) \[[@CR12]\]. Diarrhoea and rash were the most common treatment related adverse events (AEs) in patients receiving afatinib, while nausea, fatigue, decreased appetite and myelosuppression were most commonly associated with PemCis \[[@CR6]\].

Model structure and outcomes {#Sec4}
----------------------------

### Model structure {#Sec5}

An excel-based partitioned survival model (PSM) was developed to assess the cost-effectiveness of afatinib compared with pemetrexed-cisplatin (PemCis) chemotherapy for the first-line treatment of patients with locally advanced or metastatic EGFR mutation positive NSCLC. The model included three health states: progression-free (PF), progressive disease (PD) and death (Fig. [1](#Fig1){ref-type="fig"}). All patients were assumed to enter the model in the PF health state and could either remain in the same health state or transition to the PD or Death state at the beginning of each cycle \[[@CR13]\]. Patients who progressed to the PD state could stay within the same health state or progress to death; but not revert back to the PF state. The model had a time horizon of 5 years in the base-case, and a cycle length of 1 month (including a half-cycle correction).Fig. 1Partition survival model with three health states

### Treatment pathway {#Sec6}

The PSM compared two different first-line treatment arms as reflected in the LUX-lung 3. For the intervention arm, patients were assumed to receive afatinib (first-line), then PemCis (second-line) when their disease progressed, before moving to best supportive care (BSC) upon further progression. For the comparator arm, patients received PemCis (first-line), then afatinib (second-line) when their disease progressed, followed by BSC. Dosing regimens were based on the recommended dosages in the package inserts for each treatment and in line with LUX-Lung 3. Dose of PemCis was calculated assuming body surface area (BSA) of 1.6m^2^. Local oncologists were consulted to ensure the treatment algorithm in the analysis reflected routine clinical practice for the management of NSCLC in Singapore.

### Outcomes {#Sec7}

Analyses were conducted from the Singapore healthcare payer's perspective. The outcomes of interest were progression-free life years (PFLYs), overall life years (LYs), quality-adjusted life years (QALYs), the total cost of intervention and comparator treatments, as well as the incremental cost-effectiveness ratio (ICER). A discount rate of 3% was applied to both costs and outcomes.

Model parameters {#Sec8}
----------------

### Clinical efficacy data {#Sec9}

The population enrolled in LUX-Lung 3, i.e. treatment-naïve patients with stage IIIB and IV advanced EGFR mutation positive lung adenocarcinoma is reflective of the population of interest for subsidy consideration of TKIs in Singapore \[[@CR6], [@CR12]\]. The proportion of patients in each health state was derived from clinical trials \[[@CR6], [@CR12]--[@CR14]\]. The area under curve (AUC) from LUX-Lung 3 was used to determine the mean time that patients remained in each health state.

OS and PFS for patients receiving first-line treatments were extrapolated from LUX-Lung 3 (Table [1](#Tab1){ref-type="table"}). To do this, individual data points from the Kaplan-Meier (KM) curves for OS and PFS (investigator-reviewed) in the published paper were extracted using the WebPlotDigitizer developed by Rohatgi \[[@CR15]\]. Then, a curve fitting approach developed by Hoyle and Henley \[[@CR16]\] was used to estimate the underlying survival distribution from the digitised KM graphs. The curve fitting approach (with online Microsoft Excel spreadsheet and R statistics code) used survival probabilities to estimate the number of patients with events and the number censored in each time interval as a proxy for individual patient data (IPD). The tail-ends of the curves were fitted with various parametric survival models i.e. exponential, Weibull, log-logistic and log-normal. Weilbull model produced the best goodness of fit to the observed survival data based on the Akaike Information Criterion (AIC) value. Reduction factors were incorporated when combining the observed data and the extrapolated tail-end data \[[@CR17]\].Table 1Clinical efficacy data from LUX-Lung 3Afatinib armPemetrexed-cisplatin armMedian overall survival, months (95% CI)28.2 (24.6--33.6)^b^28.2 (20.7--33.2)^b^Median first-line progression free survival, months^a^11.1^c^6.7^c^*CI* confidence interval^a^95%CI was not reportedSource: ^b^ Yang et al., \[[@CR12]\]; ^c^Sequist et al, \[[@CR6]\]

In the PD health state, patients were assumed to cross over to second-line treatment. The time spent in PD was derived from the difference between AUCs of OS and first-line PFS. The proportion of time that patients received second-line treatment was derived from the literature. The median PFS was 11.9 months for afatinib (assumed from the PFS of combined gefitinib and erlotinib arms in Kim et al. \[[@CR14]\]) and 5.4 months, for PemCis (from Soria et al \[[@CR13]\]). The time spent receiving second-line treatment was assumed to remain constant across both arms irrespective of the relative time spent in the PD state.

During the remaining time in PD, patients could receive BSC as third-line therapy. The time was calculated, for each arm, by subtracting the time spent on second-line therapy from the estimated total time spent in PD (Table [2](#Tab2){ref-type="table"}).Table 2Time spent receiving each treatment during PD health stateAfatinib armPemetrexed-cisplatin armEstimated total time in PD, months21.17^a^23.92^a^Mean time receiving second-line treatment, months5.40^c^11.90^d^Mean time receiving third-line treatment (BSC), months15.77^b^12.02^b^*PD* progressive disease^a^From partitioned survival model^b^Time in BSC = time in PD -- time in second-lineSource: ^c^ Soria et al, \[[@CR13]\]; ^d^Kim et al, \[[@CR14]\]

### Adverse events {#Sec10}

Treatment related AEs grade ≥ 3 in LUX-Lung 3 were incorporated in the model. Based on local expert opinion, only AEs that had a substantial impact on patients' quality-of-life and cost of AE management were included (Table [3](#Tab3){ref-type="table"}). The model assumed AEs occurred mutually exclusive of each other. The duration of each AE was estimated from expert opinion.Table 3Incidence of grade ≥ 3 adverse eventsGrade ≥ 3 adverse eventsAfatinib (%)Pemetrexed-cisplatin (%)Neutropenia0.418.0Fatigue1.312.6Anaemia0.46.3Nausea0.93.6Diarrhoea14.40.0Rash16.20.0Vomiting3.12.7Source: Sequist et al, \[[@CR6]\]

### Cost {#Sec11}

Only direct costs were incorporated into the model including the cost of drugs, consultation visit, monitoring, BSC, and managing AEs (Table [4](#Tab4){ref-type="table"}).Table 4Unit costs included in the modelCost (SG\$)Range (SG\$)SourceCost of drugs^a^ Afatinib (per 40 mg tablet)^b^102.9598.80 to 104.29\[f\] Pemetrexed (per 500 mg vial)^b^440.54327.80 to 562.30\[f\] Cisplatin (per 50 mg vial)^b^15.6112.45 to 18.50\[f\]Cost of chemotherapy administration Facility fee/chair time (2 to 4 h)^c^272.20241.00 to 319.00\[f\] Chemotherapy preparation fee by pharmacy52.8012.00 to 80.00\[f\]Cost of consultation visit and monitoring Consultation visit74.5793.00 to 102.72\[f\] Computerised tomography-thorax scan940.00850.00 to 1000.00\[f\] Liver function test71.3052.40 to 83.90\[f\] Full blood count test26.4624.00 to 28.10\[f\] Renal panel test62.8035.20 to 81.20\[f\]Cost of best supportive care (BSC) Inpatient hospice stay (per day)275.00--\[g\] Home hospice visitNil^d^--\[g\]Cost of managing adverse event Anaemia (per episode)^e^1486.00--\[h\] Diarrhoea (per episode)^e^1382.40--\[h\]^a^Cost of drug is based on the selling price to patient^b^Dosing regimens were based on recommended dosages in package inserts for afatinib (40 mg/day), pemetrexed (500 mg/m^2^/cycle) and cisplatin (75 mg/m^2^/cycle) and assumed no vial sharing. Up to 6 cycles of chemotherapy, every 21 days, were allowed. An average Body Surface Area (BSA) of 1.6m^2^ was assumed^c^Chair time for chemotherapy is approximately 2 h and 40 min. Pemetrexed is infused over 10 min, followed by 30 min break before infusion of cisplatin over 2 h approximately^d^Home hospice visit is complementary from the hospice centre^e^Included hospital admission charges and treatment costSource: ^f^ weighted average selling price across public healthcare institutions in Singapore; ^g^ price charged by one hospice centre in Singapore; ^h^ inpatient bill sizes \[[@CR18], [@CR19]\]

The cost of afatinib and PemCis chemotherapy was estimated from the weighted average selling price across public healthcare institution in Singapore. For each PemCis chemotherapy cycle, facility fee (chemotherapy chair time of 2 to 4 h) and chemotherapy preparation fee by the pharmacy were added to the drug cost. No vial sharing for PemCis was allowed in the analysis.

Advice on frequency and types of relevant outpatient consultation visits, monitoring scans and laboratory tests for patients were sought from local oncologists. Costs for consultation visit, computerised tomography-thorax (CT) scan, liver function test, full blood count and renal panel test were sourced from public healthcare institutions.

It was assumed that patients could receive BSC at home or in hospice centres. The distribution of patients across each setting (58.3% in home care; 41.7% in hospice centre) was estimated from expert opinion.

Cost of grade ≥ 3 AEs were included only if the AEs necessitated inpatient hospitalisation (i.e. anaemia and diarrhoea) because it was assumed inpatient costs would be greater. The costs of AEs were sourced from inpatient bill sizes (including hospital admission charges and treatment costs) from public hospitals \[[@CR18], [@CR19]\]. The duration to resolve each AE was estimated by expert opinion.

### Utility values {#Sec12}

In the absence of local data, utility values for the health states for each treatment arm were extracted from a prospective, international, quality-of-life survey of patients with advanced NSCLC receiving first-, second-, or third−/fourth-line pharmacotherapy or BSC \[[@CR20]\]. Utilities were weighted by the proportion of time spent in the health states, and disutility of AEs (obtained from the UK general population \[[@CR21]\]) was also applied (Table [5](#Tab5){ref-type="table"}).Table 5Utility values for the health states and disutility values associated with adverse eventsUtility valueRangeDistributionSourceProgression-free (no AE) 1st -line afatinib and pemetrexed-cisplatin0.710.67 to 0.76Beta\[c\]^a^Progressive disease (no AE) 2nd -line afatinib and pemetrexed-cisplatin0.670.59 to 0.75Beta\[c\]^a^ 3rd-line/ Best supportive care0.590.42 to 0.77Beta\[c\]^a^Adverse events Neutropenia−0.0900.059 to 0.120Beta\[d\] Fatigue−0.0740.037 to 0.110Beta\[d\] Anaemia^b^−0.0740.037 to 0.110Beta\[d\] Nausea & vomiting−0.0480.016 to 0.080Beta\[d\] Diarrhoea−0.0470.016 to 0.077Beta\[d\] Rash−0.0330.010 to 0.055Beta\[d\]^a^The utility was then weighted by the proportion of time spent in the health state^b^Assumed from the disutility for fatigueSource: ^c^Chouaid et al, \[[@CR20]\]; ^d^Nafees et al, \[[@CR21]\]

Sensitivity analyses {#Sec13}
--------------------

One-way sensitivity analyses were conducted to explore the impact of uncertain model parameters on the ICER. Each parameter was varied independently by the lower and upper range of the 95% confidence interval or the range reported in literature.

A probabilistic sensitivity analysis (PSA) was also performed to further explore the uncertainty of input parameters by random sampling the parameters from assigned distributions. Probability distributions were selected in accordance to the nature of the variable. PFS and OS were sampled from multivariate normal distributions using the Cholesky decomposition matrix of the Weilbull distribution, whereas utility values were assumed to have a beta distribution (continuous distribution confined within interval 0 and 1). Monte Carlo simulations were repeated over 10,000 iterations to generate a distribution of ICER outcome shown as a scatterplot. There is no fixed willingness to pay (WTP) threshold to determine cost-effectiveness in Singapore, therefore a cost-effectiveness acceptability curve (CEAC) was generated to show the probability of afatinib being cost-effective across a range of WTP thresholds.

Additional scenario analyses {#Sec14}
----------------------------

Additional analyses were conducted to test the impact of different survival curve extrapolation approaches and pricing scenarios on the base case ICER. Instead of fitting the tail-end of the extrapolation KM survival curves with a Weilbull model (base case), the entire survival curves were fitted with different parametric distributions. Price discounts ranging from 10 to 50% for afatinib were also tested to simulate the potential cost savings to patients through a manufacturer's patient assistance program in Singapore.

Results {#Sec15}
=======

Base-case analysis {#Sec16}
------------------

In the base-case with a time horizon of 5 years, the ICER for afatinib versus PemCis was SG\$137,648 per QALY gained and SG\$109,172 per LY gained (Table [6](#Tab6){ref-type="table"}). The afatinib arm led to more QALYs gained compared to the PemCis arm (1.69 versus 1.58 QALYs, respectively) at an incremental cost of SG\$15,227.Table 6Summary of costs and benefits of afatinib vs PemCis - base-case analysisAfatinibPemetrexed-cisplatinIncremental differenceTotal cost (SG\$)93,95878,73115,227 Cost of PF state44,20511,23632,969 Cost of PD state49,54867,401−17,853 Cost of AE20594111Total benefit QALYs1.691.580.11 LYs2.592.450.14 PFLYs1.180.680.50ICER (QALY)----137,648ICER (LY)----109,172*ICER* incremental cost-effectiveness ratio, *QALY* quality-adjusted life year, *LY* life year, *PFLY* progression-free life year, *AE* adverse event, *PF* progression-free, *PD* progressed disease

Sensitivity analyses {#Sec17}
--------------------

One-way sensitivity analyses confirmed that the ICER was most sensitive to variations in the utility values of PF assumed for the first-line and second-line treatments, and the time horizon of the model (Fig. [2](#Fig2){ref-type="fig"}). Using the lower range of utility value for the PF state for first-line afatinib increased the ICER to SG\$239,928 per QALY, while applying the upper range of the utility value reported in the literature reduced the ICER to SG\$89,798 per QALY. Shortening the time horizon to 3 years substantially increased the ICER to SG\$217,175 per QALY, whereas lengthening the time horizon to 10 years reduced the ICER to SG\$100,632 per QALY. Varying the discount rate and disutility associated with AEs had less impact on the ICER result.Fig. 2One way sensitivity analysis tornado diagram. QALY: quality-adjusted life year; PF: progression-free; PD: progressed disease; BSC: best supportive care; PemCis: pemetrexed-cisplatin

The PSA result was congruent with the base-case analysis where afatinib was consistently more effective and also more costly than PemCis in all 10,000 simulations (Fig. [3](#Fig3){ref-type="fig"}). The probabilistic ICER for afatinib versus PemCis was SG\$137,391 per QALY. The CEAC (Fig. [4](#Fig4){ref-type="fig"}) showed that afatinib had zero probability of being cost-effective when the WTP threshold was below SG\$110,000 per QALY and that there was only a 50% likelihood of it being more cost-effective than PemCis at a WTP threshold of SG\$186,000 per QALY.Fig. 3Probabilistic cost-effectiveness scatterplot. Each dot represents the ICER for 1 simulationFig. 4CEAC showing the likelihood of afatinib being cost-effective compared to pemetrexed-cisplatin across different WTP thresholds. CEAC: cost-effectiveness acceptability curve; WTP: willingness to pay

Additional analyses {#Sec18}
-------------------

Results for the additional scenario analyses are shown in Table [7](#Tab7){ref-type="table"}. Applying the Weilbull parametric fit to the entire KM curves produced a lower ICER than the base-case scenario (SG\$129,416 vs. SG\$137,648 per QALY). Conversely, applying an exponential parametric fit to the model produced a higher ICER of SG\$143,658 per QALY. The pricing analyses showed that reducing the cost of afatinib by 10% to 50% lowered the ICER to SG\$128,348 - SG\$91,147 per QALY. None of the scenario analyses brought the ICER into an acceptable range of cost-effectiveness in Singapore's context.Table 7Summary of cost and benefit in the additional scenario analysisCost(SG\$)QALYsLYsPFLYsICER (SG\$/QALY)Independent model with parametric fitting^a^ Weilbull  PemCis76,6791.542.380.66  Afatinib92,4861.662.551.10129,416 Exponential  PemCis73,7751.532.370.71  Afatinib92,5071.662.551.18143,658 Log-normal  PemCis76,8511.572.430.70  Afatinib94,9661.722.611.32126,202 Log-logistic  PemCis76,0461.572.430.73  Afatinib94,7641.712.601.34133,627Pricing scenario^b^ 10% reduction  PemCis75,6821.582.450.68  Afatinib89,8801.692.591.18128,348 20% reduction  PemCis72,6321.582.450.68  Afatinib85,8021.692.591.18119,048 30% reduction  PemCis69,5831.582.450.68  Afatinib81,7241.692.591.18109,747 40% reduction  PemCis66,5341.582.450.68  Afatinib77,6461.692.591.18100,447 50% reduction  PemCis63,4851.582.450.68  Afatinib73,5681.692.591.1891,147*ICER* incremental cost-effectiveness ratio, *QALY* quality-adjusted life year, *LY* life year, *PFLY* progression-free life year, *PemCis* pemetrexed-cisplatin^a^Progression-free and overall survival curves of both intervention arms extrapolated from Kaplan-Meier data from trial, with parametric curve fitting from time = 0 to tail-end^b^Pricing scenario with various discounting on the cost of afatinib. Afatinib was modelled in the first-line for the afatinib arm, and post-progression (second-line) for the PemCis arm, therefore the total cost of both arms reduced as a result of the reduction in selling price of afatinib

Discussion {#Sec19}
==========

In Singapore, there is increasing use of afatinib and other TKIs for the treatment of NSCLC, due to their improved progression-free survival outcomes, favourable AE profiles and the convenience they offer patients through oral administration compared to chemotherapy. However, TKIs are substantially more costly than platinum doublet chemotherapy, making them largely unaffordable for most patients. To our best knowledge, this is the first study conducted to address the cost-effectiveness of afatinib as first-line therapy for patients with EGFR mutation-positive NSCLC in Singapore. It complements a previous cost-effectiveness analysis conducted in Singapore that suggested EGFR mutation testing coupled with gefitinib was the dominant treatment strategy, compared with no mutation testing plus chemotherapy \[[@CR22]\].

Clinical trials informing this study consistently showed no statistically significant improvement in OS for afatinib compared with platinum-based chemotherapy for EGFR mutation-positive NSCLC, although significant improvements in PFS were demonstrated. These results are also consistent with studies of other TKIs (erlotinib and gefitinib) compared with platinum doublet chemotherapy \[[@CR5], [@CR6], [@CR8]--[@CR12], [@CR23]--[@CR28]\]. Although OS remains the gold standard metric of benefit for clinical trials involving therapeutic oncology agents, successive lines of treatment, patient crossover and increased post-progression survival may dilute treatment effects. While surrogate endpoints such as PFS potentially offer more feasible options to measure clinical benefit, allowing for shorter trial duration and smaller patient cohorts, the correlation between PFS and OS requires validation given it is context dependent and contingent on disease, stage, patient population and therapy \[[@CR29]\].

Investigator-reviewed rather than independent-reviewed PFS curve was used in our base-case analysis to mimic patient assessments in real-world clinical practice. We acknowledge that there are limitations with both approaches, therefore selection of appropriate estimates requires careful consideration. Although independent-review of PFS may lessen some potential investigator biases, it can introduce informative censoring \[[@CR30], [@CR31]\]. On the other hand, meta-analysis shows that investigator-review can provide reliable estimates with little evidence of systematic evaluation bias \[[@CR32]\]. Both investigator-review (median PFS of 11.1 months for afatinib, 6.7 months for PemCis) and independent-review (median PFS of 11.1 months for afatinib, 6.9 months for PemCis) curves yielded similar PFS results in LUX-Lung 3 \[[@CR6]\]. For our CEA, any uncertainty of PFS was further addressed by probabilistic sensitivity analysis and scenario analyses with different survival curve extrapolation approaches, therefore the choice of curve was not considered to have a material impact on our results.

In cost-effectiveness modelling, when applying a parametric survival curve to the tail-end of empirical KM data, jump-off bias is a common phenomenon where the observed KM curve and the extrapolated or forecasted fitted parametric curve do not join smoothly. This is most evident when running PSA where the forecasted OS value randomly sampled for a particular month may be unrealistically higher than the previous month, if the reduction factor was not applied. In our base-case analysis, a jump-off bias adjustment was crucial because the PFS and OS survival curves from the trial were relatively short (22 & 49 months respectively). To tackle this issue, reduction factors were applied to both OS and PFS curves to combine the observed data and the extrapolated tail-end data to prevent any jump-off bias and in turn generate a 'smooth' curve. For instance, OS in each forecasted month was calculated as the product of the OS estimated by the Weilbull model, and the ratio of the last observed OS value in the curve and the OS estimated by the Weilbull model for the last observed OS value.

It is worth noting that the cost of the PD health state for both intervention arms was higher than for the PF health state, largely driven by the cost and assumed substantial duration of third-line treatment with BSC. Patients receiving first-line afatinib crossed over to second-line PemCis on progression which was associated with a shorter PFS period of 5.4 months, and resulted in a long duration (16 months) of BSC on further disease progression. Patients treated with first-line PemCis received BSC third-line for 11.5 months in the model.

Our base-case analysis reveals that afatinib is not a cost-effective treatment option at its current price. A key contributor to the high ICER value was the cost of afatinib relative to PemCis. This was reflected in the incremental difference in first-line drug cost of SG\$34,783, which was driven by the longer PFS duration associated with afatinib, thus accounting for more daily doses of afatinib until progression, whereas PemCis costs were capped at 6 cycles. Similarly, as patients receiving first-line PemCis were assumed to cross-over to afatinib second-line on progression, the cost of the PD health state in the PemCis arm was thus higher than the afatinib arm. Although different pricing scenarios were tested, even reducing the cost of afatinib by 50% only lowered the ICER to SG\$91,147 per QALY gained, which is unlikely to be considered cost-effective in the Singapore setting.

Our results are comparable with published ICERs for TKIs in overseas settings. An analysis of first-line treatment of patients with EGFR mutation-positive NSCLC in the UK reported an ICER for gefitinib compared with PemCis ranging from £23,615 (maximum of 6 cycles) to £64,481 per QALY gained (a maximum of 5 cycles). The analysis used a Markov economic model and a similar 5-year time horizon \[[@CR33]\]. Ting et al. \[[@CR34]\] assessed the cost-effectiveness of erlotinib, afatinib and PemCis for first-line treatment of advanced epithelial EGFR mutation-positive NSCLC in the US. The authors also suggested erlotinib was more effective and more costly compared with PemCis, with an ICER of US\$40,106 per QALY gained. However, contrary to our results, afatinib was found to be cost saving in the US, largely due to the fact that it had the lowest cost price (followed by PemCis and then erlotinib) while in Singapore, PemCis is the least expensive treatment option, followed by erlotinib, then afatinib based on current cost prices.

One-way sensitivity analysis was performed to assess the key drivers of the model by varying the input parameters. The key driver of ICER was the utility values used, which were extracted from published literature due to the absence of local data. There is little published data on the related preferences of patients in different health states during NSCLC disease progression, and this is a key limitation of our study. For the purposes of our analysis, we adapted utility values from a multi-country, quality-of-life survey of patients with advanced NSCLC, and applied disutility values associated with AEs which were sourced from another study conducted in the UK general public. Combining the utility values from two studies consisting of different populations is not ideal and may affect the validity of the results.

Our model had a lifetime horizon of 5 years in the base case, which was similar to the published CEA conducted in the UK \[[@CR31]\]. This time period was considered clinically plausible given Singapore's cancer registry \[[@CR1]\] showed that the 5-year age-standardised observed survival rate for stage IV lung cancer is low (3.14% for men and 4.82% for women). Sensitivity analysis confirmed that the model was sensitive to the time horizon. Prolonging the time horizon to 10 years reduced the ICER considerably because the longer time horizon allowed for all QALYs to be fully captured. The increase in QALY was driven by the increase in LY while the PFLY remained constant.

There are several limitations of our economic model that may affect its robustness. Firstly, both utilities studies which informed inputs in the model were conducted in western countries (9% of the population were Asian in the study by Chouaid et al. \[[@CR21]\], whereas the ethnicity of the study population in Nafees et al. \[[@CR22]\] was not reported); thus, utility values may not be wholly generalisable to Asian patients in Singapore. Secondly, the model closely mimicked the trial design -- i.e. after receiving first-line afatinib or PemCis, patients were allowed to switch to subsequent therapy upon disease progression. Hence, the model did not allow for the use of maintenance treatments such as erlotinib or pemetrexed which may not be true to local clinical practice.

Thirdly, the PFS data for second-line afatinib and PemCis were derived from published trials which were thought to best fit the treatment sequence employed in the model. No published data that was identical to the treatment sequencing in the model was available. In addition, local clinical guidelines recommend pemetrexed-carboplatin and pemetrexed-cisplatin chemotherapy for the first-line treatment of non-squamous advanced NSCLC in view of its better outcome than platinum doublet chemotherapy without pemetrexed. However, our analysis did not include pemetrexed-carboplatin as a comparator to afatinib, in the absence of trial data.

A further limitation of our study was the lack of cost data for AEs treated in an outpatient setting. Excluding the cost of neutropenia for example may overestimate the ICER given the rate of neutropenia was reported to be higher in the PemCis treatment arm of LUX-Lung 3. In Singapore, it is likely that patients who experience neutropenia may not require hospitalisation and could be managed in an outpatient setting with granulocyte colony growth factors (G-CSF). Similarly, LUX-Lung 3 reported higher rates of diarrhoea and rash in the afatinib treatment arm. The cost of outpatient therapies for these AEs, such anti-diarrhoea tablet, hydration solution, moisturiser and antihistamine were not included in the model. For our CEA, only the costs of AEs that necessitated inpatient hospitalisation were included. The cost of G-CSF and other over-the-counter medications were considered negligible because they had a marginal overall cost impact compared to hospital admission. In addition, the cost of G-CSF is halved since the entry of biosimilar in 2014 and its cost is expected to continue to decline given multiple biosimilars are now available.

Lastly, our analysis did not account for vial sharing of pemetrexed. Hence this would tend to underestimate the ICER given that vial sharing is common practice in Singapore as most patients are treated in one of the two large specialised cancer centres within the public healthcare institutions.

Conclusions {#Sec20}
===========

TKIs remain a very costly first-line treatment option for advanced EGFR mutation-positive NSCLC as currently none of the TKIs have been shown to improve overall survival. Our analysis showed that afatinib is not a cost-effective first-line treatment in Singapore and does not represent good value for limited health care dollars compared with pemetrexed-cisplatin. The findings from our study will be useful to inform local healthcare decision-making and resource allocations for NSCLC treatments, together with other considerations such as clinical effectiveness, safety and affordability of TKIs.
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